[go: up one dir, main page]

CY1120741T1 - Θεραπεια οζωδους σκληρυνσης - Google Patents

Θεραπεια οζωδους σκληρυνσης

Info

Publication number
CY1120741T1
CY1120741T1 CY181100572T CY181100572T CY1120741T1 CY 1120741 T1 CY1120741 T1 CY 1120741T1 CY 181100572 T CY181100572 T CY 181100572T CY 181100572 T CY181100572 T CY 181100572T CY 1120741 T1 CY1120741 T1 CY 1120741T1
Authority
CY
Cyprus
Prior art keywords
treatment
scrub
nose
neurodermatological
disorders
Prior art date
Application number
CY181100572T
Other languages
English (en)
Inventor
William Berg
John Benedetto
Ingrid Elmroth
Heidi Lane
David Lebwohl
William Sellers
Michael Stumm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37944274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120741(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602123A external-priority patent/GB0602123D0/en
Priority claimed from GB0603568A external-priority patent/GB0603568D0/en
Priority claimed from GB0604593A external-priority patent/GB0604593D0/en
Priority claimed from GB0605760A external-priority patent/GB0605760D0/en
Priority claimed from GB0609698A external-priority patent/GB0609698D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1120741T1 publication Critical patent/CY1120741T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παράγωγα ραπαμυκίνης για χρήση στη θεραπεία νευροδερματικών διαταραχών.
CY181100572T 2006-02-02 2018-05-25 Θεραπεια οζωδους σκληρυνσης CY1120741T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0602123A GB0602123D0 (en) 2006-02-02 2006-02-02 Organic compounds
GB0603568A GB0603568D0 (en) 2006-02-22 2006-02-22 Organic compounds
GB0604593A GB0604593D0 (en) 2006-03-07 2006-03-07 Organic compounds
GB0605760A GB0605760D0 (en) 2006-03-22 2006-03-22 Organic compounds
GB0609698A GB0609698D0 (en) 2006-05-16 2006-05-16 Organic compounds
PCT/EP2007/000818 WO2007088034A2 (en) 2006-02-02 2007-01-31 Tuberous sclerosis treatment

Publications (1)

Publication Number Publication Date
CY1120741T1 true CY1120741T1 (el) 2019-12-11

Family

ID=37944274

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100572T CY1120741T1 (el) 2006-02-02 2018-05-25 Θεραπεια οζωδους σκληρυνσης

Country Status (21)

Country Link
US (1) US20100305150A1 (el)
EP (2) EP3348265A1 (el)
JP (2) JP5639743B2 (el)
KR (2) KR20140016439A (el)
CN (1) CN104000818B (el)
AU (1) AU2007211613C1 (el)
BR (1) BRPI0707684B1 (el)
CA (1) CA2637255C (el)
CY (1) CY1120741T1 (el)
DK (1) DK1983984T3 (el)
ES (1) ES2672627T3 (el)
HK (1) HK1251156A1 (el)
HU (1) HUE037890T2 (el)
LT (1) LT1983984T (el)
MX (1) MX339116B (el)
PL (1) PL1983984T3 (el)
PT (1) PT1983984T (el)
RU (1) RU2473343C2 (el)
SI (1) SI1983984T1 (el)
TR (1) TR201807065T4 (el)
WO (1) WO2007088034A2 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672627T3 (es) 2006-02-02 2018-06-15 Novartis Ag Tratamiento de la esclerosis tuberosa
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20150338425A1 (en) * 2011-11-14 2015-11-26 The Brigham And Women's Hospital, Inc. Treatment and prognosis of lymphangioleiomyomatosis
ES2752021T3 (es) 2013-02-01 2020-04-02 Glialogix Inc Composiciones y métodos para el tratamiento de enfermedades neurodegenerativas y otras enfermedades
WO2014137978A1 (en) * 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
PT2976074T (pt) * 2013-03-19 2020-03-11 Univ Pompeu Fabra Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronais
CA2926719C (en) 2013-10-08 2020-11-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CA2939342A1 (en) 2014-02-11 2015-08-20 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HRP20230863T1 (hr) 2014-04-04 2023-11-10 AI Therapeutics, Inc. Inhalacijska formulacija rapamicina, namijenjena liječenju stanja povezanih sa starenjem
US20170304276A1 (en) 2014-10-07 2017-10-26 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP6541124B2 (ja) 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
CA3032473A1 (en) 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
CN113710232A (zh) 2019-02-20 2021-11-26 人工智能治疗公司 局部雷帕霉素制剂及其在治疗面部血管纤维瘤和其他皮肤病中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
CN1124276C (zh) * 1995-06-09 2003-10-15 诺瓦蒂斯有限公司 雷帕霉素衍生物
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
DK3351246T3 (da) 2001-02-19 2019-06-03 Novartis Pharma Ag Rapamycinderivat til behandling af en solid tumor, som er associeret med dereguleret angionese
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
CN100374158C (zh) * 2002-08-12 2008-03-12 密执安州立大学董事会 降低细胞atp水平的药剂在制备药物中的应用
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20040266811A1 (en) * 2002-11-08 2004-12-30 Weinstein David E. Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
AU2004212919A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
WO2005005434A1 (en) * 2003-07-08 2005-01-20 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1648900A4 (en) * 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2006071966A2 (en) * 2004-12-29 2006-07-06 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
ES2672627T3 (es) 2006-02-02 2018-06-15 Novartis Ag Tratamiento de la esclerosis tuberosa

Also Published As

Publication number Publication date
WO2007088034A3 (en) 2007-11-01
EP3348265A1 (en) 2018-07-18
JP2009525294A (ja) 2009-07-09
LT1983984T (lt) 2018-06-11
AU2007211613C1 (en) 2018-01-04
BRPI0707684A2 (pt) 2011-05-10
AU2007211613A1 (en) 2007-08-09
RU2473343C2 (ru) 2013-01-27
BRPI0707684B1 (pt) 2021-10-13
MX339116B (es) 2016-05-12
TR201807065T4 (tr) 2018-06-21
DK1983984T3 (en) 2018-06-14
KR20140016439A (ko) 2014-02-07
SI1983984T1 (en) 2018-06-29
BRPI0707684A8 (pt) 2017-12-26
RU2008135131A (ru) 2010-03-10
CN104000818A (zh) 2014-08-27
AU2007211613B2 (en) 2011-04-28
PL1983984T3 (pl) 2018-08-31
JP5639743B2 (ja) 2014-12-10
CA2637255A1 (en) 2007-08-09
PT1983984T (pt) 2018-06-14
HK1251156A1 (en) 2019-01-25
HUE037890T2 (hu) 2018-09-28
JP2013224298A (ja) 2013-10-31
ES2672627T3 (es) 2018-06-15
EP1983984B1 (en) 2018-03-07
KR20080090493A (ko) 2008-10-08
EP1983984A2 (en) 2008-10-29
CN104000818B (zh) 2017-11-21
CA2637255C (en) 2018-06-12
WO2007088034A2 (en) 2007-08-09
US20100305150A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
BRPI0810524A2 (pt) Derivado de (aza)indol e uso do mesmo para propósitos médicos
HUE038588T2 (hu) IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA201171367A1 (ru) Винилиндазолильные соединения
NL1036306A1 (nl) Lithographic apparatus and in-line cleaning apparatus.
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
BRPI0910780A2 (pt) uso de antagonistas de opióides para o tratamento da retenção urinária
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
EA201000258A1 (ru) Новые гербициды
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
EP2076239A4 (en) COMBINATION THERAPY
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
IL199214A0 (en) New combination for use in the treatment of inflammatory disorders